Bristol-Myers Squibb Co. | BMY |
| Bristol-Myers Squibb Co. (BMY) |
|
|
| NYSE:BMY |
Last Trade: Thursday, August 05, 2010 @ 4:21:12 PM |
| Last Price: 26.38 |
Change: ($+0.35 +1.3446%) |
| Open: |
25.83 |
Prev. Close: |
26.03 |
| Day's High: |
26.38 |
Low: |
25.80 |
| 52-Week High: |
32.35 |
52-Week Low: |
21.75 |
| Bid: |
26.34 / 400 |
Ask: |
26.40 / 200 |
| Volume: |
12,234,117 |
Outstanding: |
1,978,511,425 |
| Market cap: |
$43 B
|
|
|
|
|
| Bristol-Myers Squibb, through its divisions and subsidiaries, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other healthcare related products. Co. has three reportable segments: Pharmaceuticals, Nutritionals and Other Healthcare. The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business. The Nutritionals segment consists of Mead Johnson Nutritionals, primarily an infant formula and children's nutritionals business. The Other Healthcare segment consists of ConvaTec and Medical Imaging businesses. |
Bristol-Myers Squibb Co. Press ReleasesNew Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis Patients to be Presented - Tuesday, June 15, 2010
Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previ - Saturday, June 05, 2010
SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to - Saturday, June 05, 2010
Bristol-Myers Squibb to Present Data on 13 Oncology Compounds During 2010 American Society of Clinic - Thursday, May 20, 2010
Bristol-Myers Squibb Receives Complete Response Letter from FDA for Belatacept - Saturday, May 01, 2010
StockSource.us Reports MNDP - Breakout Penny Stock - Thursday, April 08, 2010
LiquidStockReport.com Reports on Stocksource.us - Thursday, April 01, 2010
Investment overview released on Bristol-Myers Squibb (NYSE: BMY) - Thursday, March 25, 2010
LiquidStockReport.com Green Energy Live Looks at Solar Energy - Thursday, March 11, 2010
LiquidStockReport.com GELV Peck Solid & Well Run' - Thursday, March 11, 2010
StockSource.us Reports Green Energy Live Moves Deeper into Energy Markets - Tuesday, March 09, 2010
ADVANCE-2 Study Results Demonstrate Investigational Anticoagulant Apixaban Was Statistically Superio - Thursday, March 04, 2010
Bristol-Myers Squibb Announces Dividend - Tuesday, March 02, 2010
FDA Advisory Committee Recommends Approval of Belatacept, an Investigational Agent for Prophylaxis o - Tuesday, March 02, 2010
Picksthatmove.com Provides Investment Opinion on Pfizer, Johnson & Johnson, GlaxoSmithKline, Bayer A - Friday, February 26, 2010
StockSource.us Reports Hot Penny Stock Pick GELV - Friday, February 12, 2010
LiquidStockReport.com GELV Strengthens Position - Friday, February 12, 2010
StockSource.us Reports GELV Looking to Make its Mark - Thursday, February 11, 2010
LiquidStockReport.com-GELV Positioned for Growth - Tuesday, February 09, 2010
Chartpoppers.com releases Investment Analysis on Bristol Myers Squibb Co (NYSE: BMY) - Monday, February 08, 2010
Chartpoppers.com releases a Consolidated Investment Analysis on Bristol-Myers Squibb (NYSE: BMY) - Thursday, December 24, 2009
ADDING MULTIMEDIA Bristol-Myers Squibb And Pfizer Announce Plans To Submit Regulatory Filing For Api - Saturday, December 05, 2009
Bristol-Myers Squibb And Pfizer Announce Plans To Submit Regulatory Filing For Apixaban In Europe - Friday, December 04, 2009
Bristol-Myers Squibb and Mead Johnson Announce Amendment and Extension of Exchange Offer - Friday, December 04, 2009
U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Treatment of Irritability - Friday, November 20, 2009
Bristol-Myers Squibb Announces Split-Off of Mead Johnson - Sunday, November 15, 2009
FDA Approves Labeling Update for REYATAZ® (atazanavir sulfate) Capsules to Include 96-Week Data for - Thursday, November 05, 2009
Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in He - Saturday, October 31, 2009
BARACLUDE® (entecavir) Demonstrated Greater Antiviral Efficacy Compared to Adefovir in New Study of - Saturday, October 31, 2009
Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common - Friday, October 23, 2009
Taisho (TYO:4535) Agreed to Buy Bristol-Myers (NYSE:BMY) Asian Assets For US$310M - Wednesday, September 16, 2009
Bristol-Myers Squibb Company Announces Sale to Taisho Pharmaceutical Co Ltd., of Its OTC Assets in A - Wednesday, September 16, 2009
Bristol-Myers Squibb Announces Acceptance of Submission for Belatacept Biologic License Application - Thursday, September 03, 2009
Bristol-Myers Squibb Completes Acquisition of Medarex, Inc. - Tuesday, September 01, 2009
New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of P - Sunday, August 30, 2009
Endocyte Says Collaboration Paying Off - Wednesday, August 26, 2009
Bristol-Myers Squibb Extends Tender Offer for Medarex, Inc. - Thursday, August 20, 2009
Zacks Analyst Blog Highlights: eBay Inc., ZymoGenetics, Inc., Bristol-Myers Squibb, Express Scripts, - Thursday, April 16, 2009
Bristol-Myers Squibb Announces Extension of U.S. Agreement for ABILIFY® and Establishment of an Onco - Monday, April 06, 2009
Bristol-Myers Squibb Enters Global Collaboration with Nissan Chemical and Teijin Pharma on Novel Atr - Thursday, March 05, 2009
Technical Trade Alerts on market movers: CNO, SUN, IP, BMY, GILD, INTC - Wednesday, March 04, 2009
Bristol-Myers Squibb Announces Organizational Changes; Names Four to Company’s Executive Committee - Tuesday, March 03, 2009
Bristol-Myers Squibb Announces Dividend - Tuesday, March 03, 2009
Zacks Releases Four Powerful ''Buy'' Stocks: LaBranche & Co., Inc., Bristol Myers Squibb Co., TransD - Thursday, February 19, 2009
Bristol-Myers Squibb Foundation Announces Funding of More Than $1.17 Million to Bridge Gaps in Hepat - Friday, February 13, 2009
ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplementa - Friday, January 23, 2009
Bristol-Myers Squibb and ZymoGenetics Enter Global Collaboration on Novel Hepatitis C Compound - Tuesday, January 13, 2009
Bristol-Myers Squibb Announces Dividend - Thursday, December 18, 2008
New Data Demonstrate Significant Improvement in Progression-Free Survival for Triple Negative Metast - Friday, December 12, 2008
Zacks Releases Four Powerful ''Buy'' Stocks: Fuel Systems Solutions, Bristol-Myers Squibb Co., Carte - Thursday, December 11, 2008
Rationale and Design of CURRENT-OASIS 7 Study Published in American Heart Journal - Thursday, November 06, 2008
New Data Suggest Long-Term Treatment with BARACLUDE(R) (entecavir) May Reduce Liver Damage Caused by - Sunday, November 02, 2008
Data Demonstrate ORENCIA(R) (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Qual - Tuesday, October 28, 2008
Study Results Demonstrate More Patients With Early Erosive Rheumatoid Arthritis Treated With ORENCIA - Monday, October 27, 2008
96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ(R) (ataz - Sunday, October 26, 2008
Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Respo - Thursday, October 23, 2008
Bristol-Myers Squibb to Announce Results for the Third Quarter of 2008 on October 23 - Wednesday, October 15, 2008
U.S. Food & Drug Administration Approved the use of REYATAZ(R) (atazanavir sulfate) Boosted with Rit - Wednesday, October 01, 2008
Bristol-Myers Squibb to Commence Cash Tender Offer for ImClone Systems at $62.00 per share - Monday, September 22, 2008
Bristol-Myers Squibb Announces Filing of IPO Registration Statement for Mead Johnson Nutrition Compa - Tuesday, September 16, 2008
ImClone Systems Submits Letter to Bristol-Myers Squibb - Thursday, September 11, 2008
Study Published in New England Journal of Medicine Shows ERBITUX(R) Improved Survival in First-Line - Thursday, September 11, 2008
New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Pati - Tuesday, September 02, 2008
Ingenuity Systems Announces Multi-Year Deal With Bristol-Myers Squibb for IPA - Tuesday, September 02, 2008
Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program - Wednesday, August 27, 2008
ADDING MULTIMEDIA NJ, CT, NY & MD School Districts Join Program That Teaches High School Students Ho - Thursday, August 14, 2008
CORRECTING and REPLACING CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r - Wednesday, August 06, 2008
Dako Enters into Collaboration with Bristol-Myers Squibb for Pharmacodiagnostics - Friday, June 27, 2008
Bristol-Myers Squibb Completes Acquisition of Kosan Biosciences Incorporated - Friday, June 27, 2008
Bristol-Myers Squibb Announces Dividend - Wednesday, June 11, 2008
ADDING MULTIMEDIA Newark High School Students and Research Scientists Discuss Challenges of Making M - Tuesday, June 03, 2008
New Ipilimumab Survival Data in Patients with Metastatic Melanoma Presented at American Society of C - Monday, June 02, 2008
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advance - Sunday, June 01, 2008
Bristol-Myers Squibb Reaffirms 2008 Earnings Guidance - Friday, May 30, 2008
Zacks Analyst Interview Highlights: Pfizer, Bristol Myers Squibb, Sanofi-Aventis and Merck - Wednesday, May 28, 2008
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Add-On Treatment to Lithium - Friday, May 09, 2008
ABILIFY(R) (aripiprazole) Receives Expanded Indications for Maintenance Treatment in Both Pediatric - Friday, May 09, 2008
BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir a - Sunday, April 27, 2008
Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab - Saturday, April 26, 2008
Get this stock quote and other market data from XML Stock Quotes.com
|
